Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.
| Added by | celine.gongora |
|---|---|
| Group name | EquipeCG |
| Item Type | Attachment |
| Title | PubMed entry |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/35390339 |
| Accessed | 2022/08/29 - 17:31:13 |
| Date Added | 2022/08/29 - 15:31:13 |
| Date Modified | 2022/08/29 - 15:31:13 |
| Parent item | Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial |
Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).
U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)
Institut de Recherche en Cancérologie de